Avantor, Inc. (AVTR) Stock Analysis
Healthcare · Medical Instruments & Supplies · NYSE
Avantor, Inc. (AVTR) posted $6.55B in revenue for fiscal 2025 (down 3.4% year over year), with a net loss of $530.20M, and has compounded revenue about 0.5%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Avantor, Inc.
Avantor, Inc. has grown revenue from $1.25B to $6.55B over the last 9 fiscal years, compounding about 0.5% a year. The most recent year was down 3.4%, so growth has cooled from its longer-run pace.
Net margin sits at -8.1%, down 18.6 points year over year on a 32.7% gross margin. It carries about $3.95B of total debt.
At today's valuation the market is pricing in roughly 2.1% annual free-cash-flow growth — versus the -10.6% it actually delivered over the last five years, so the price already assumes a step-up from the recent record. The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Avantor, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Avantor, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.25B | $5.86B | $6.04B | $6.39B | $7.39B | $7.51B | $6.97B | $6.78B | $6.55B |
| Gross profit | $432.80M | $1.82B | $1.92B | $2.08B | $2.50B | $2.60B | $2.36B | $2.28B | $2.14B |
| Net income | $-112.70M | $-86.90M | $37.80M | $116.60M | $572.60M | $662.30M | $321.10M | $711.50M | $-530.20M |
| Net margin | -9.0% | -1.5% | 0.6% | 1.8% | 7.8% | 8.8% | 4.6% | 10.5% | -8.1% |
Source: Avantor, Inc. SEC filings (10-K).
Avantor, Inc.: 3 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 11.9% over 4 years (609.7M → 682M) — existing holders' stakes are being diluted.
- Heavy debt loadTotal debt of $4007.9M is 6.4× last year's operating cash flow — it would take years of cash flow to clear.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -8.1%).
What growth is priced into AVTR stock?
At today's market cap of $6.59B, Avantor, Inc. is priced for free-cash-flow growth of about 2.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $495.00M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -10.6%/yr over the last five fiscal years and revenue 0.5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 9 years of Avantor, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AVTR in your portfolio →
Avantor, Inc. financial history by metric
Compare Avantor, Inc. with peers
About Avantor, Inc.
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Avantor, Inc. — frequently asked questions
What is Avantor, Inc.'s revenue?
Avantor, Inc. (AVTR) reported revenue of $6.55B for fiscal year 2025, down 3.4% from the prior year, according to its SEC filings.
Is Avantor, Inc. profitable?
No — AVTR reported a net loss of $-530.20M in fiscal 2025.
What is AVTR's P/E ratio?
Avantor, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Avantor, Inc. growing?
AVTR's revenue grew at roughly 0.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Avantor, Inc. have?
As of fiscal year 2025, AVTR carried roughly $3.95B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Avantor, Inc.'s gross margin?
AVTR's gross margin was 32.7% in fiscal 2025 — gross profit of $2.14B on revenue of $6.55B.
What is Avantor, Inc.'s market cap?
Avantor, Inc. (AVTR) has a market capitalization of about $6.59B, based on the latest data in our nightly-refreshed cache.
When does Avantor, Inc.'s fiscal year end?
AVTR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into AVTR stock?
At today's market cap of $6.59B, Avantor, Inc. is priced for free-cash-flow growth of about 2.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $495.00M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -10.6%/yr over the last five fiscal years and revenue 0.5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Avantor, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.